Relmada Therapeutics Joins Russell 2000 Index And Russell 3000 Index

Relmada Therapeutics, Inc. (NASDAQ:RLMD, “Relmada” or the “Company”))), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced that the Company joined the Russell 2000® Index and the Russell 3000® Index effective after the U.S. market closed on June 26, 2026, as part of the Russell Indexes reconstitution.